Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA TrialRuoxi Hong, Shusen Wang, Qiufan Zheng et al.|Journal of Clinical Oncology|2025Cited by 12
Circ_ZNF778_006 Promoted ESCC Progression Via Enhance the Activity of HIF-1Aby Sponging miR-18b-5pXincheng Su, Zhijun Huang, Xianzhe Si et al.|SSRN Electronic Journal|2022Cited by 0